Home' Australian Pharmacist : Australian Pharmacist February 2016 Contents Australian Pharmacist February 2016 I ©Pharmaceutical Society of Australia Ltd.
CONTINUING PROFESSIONAL DEVELOPMENT
Australian Pharmacist Continuing Professional
Development (CPD) is a central element of PSA’s
CPD & PI program.
The CPD section is recognised under the PSA
CPD & PI program as a Group 2 activity. Members
can choose which articles they want to answer
questions on and get CPD credits based on the
questions they answer.
CPD credits are allocated based on the length of
the article and the complexity of the information
presented. A minimum of 6 out of 8 questions, 4 out
of 5 questions, or 3 out of 4 questions correct is
required for the allocation of Group 2 CPD credits.
PSA members can answer online at www.psa.org.au.
Login to submit your answers online. If you
do not have member access details, you can
request them via a link from the login page.
Select Submit Answers.
Select Australian Pharmacist CPD.
Submit your answers online before
1 April 2016 at www.psa.org.au and
receive automatic feedback.
1. Apart from perampanel, which other
antiepileptic drug has some anti-
2. Which of the following MOST
accurately describes the mechanism
of action of perampanel?
a) It enhances the activity of gamma-
aminobutyric acid (GABA), the major
inhibitory neurotransmitter in the brain.
b) It blocks sodium channels, thereby
preventing repetitive neuronal
c) It reduces neuronal excitation by
selectively blocking AMPA receptor-
mediated synaptic transmission.
d) It antagonises the kainate subtype of
3. What is the current recommendation
regarding the role of perampanel in
the treatment of epilepsy?
a) It can be used as second-line
monotherapy in the treatment of
b) It can be used as first-line adjunctive
therapy in the treatment of focal
c) It can be used as first-line adjunctive
therapy in the treatment of generalised
d) It can be used as second-line adjunctive
therapy in the treatment of focal seizures.
4. Which of the following is an
appropriate counselling point for a
patient presenting with a first-time
prescription for perampanel?
a) The tablets should be taken once
daily, preferably in the morning with
b) Moderate alcohol consumption while
taking perampanel is unlikely to have
any harmful effects.
c) Perampanel can cause serious
behavioural reactions which usually
occur after long-term therapy in
patients with a history of psychiatric
d) Perampanel can cause dizziness,
drowsiness and balance disturbances,
and increase the risk of falls.
5. A customer asks you to dispense
her script for perampanel, which
the doctor has just added to her
current oxcarbazepine therapy. What
interaction is likely to occur between
these two medicines?
a) Perampanel is likely to cause a
~30% increase in serum levels of
b) Oxcarbazepine is likely to cause a ~50%
increase in serum levels of perampanel.
c) Perampanel is unlikely to have
any influence on serum levels of
d) Oxcarbazepine is likely to cause a ~20%
decrease in serum levels of perampanel.
10. Ochoa JG. Antiepileptic drugs. Revised June 2015.
Medscape. At: http://emedicine.medscape.com/
11. Product information. eMIMs cloud. Sydney: MIMS Australia;
12. Steinhoff BJ. Introduction: perampanel – new mode
of action and new option for patients with epilepsy.
Epilepsia 2014;55(Suppl.1):1–2 . At: onlinelibrary.wiley.com/
13. Patsalos PN. The clinical pharmacology profile of the new
antiepileptic drug perampanel: a novel noncompetitive
AMPA receptor antagonist. Epilepsia 2015;56(1):12–27. At:
14. Krauss GL. Perampanel: a selective AMPA antagonist for
treating seizures. Epilepsy Currents 2013;13(6):269–72.
15. Steinhoff BJ. The AMPA receptor antagonist perampanel in
the adjunctive treatment of partial-onset seizures: clinical
trial evidence and experience. Ther Adv Neurol Disord
2015;8(3):137–47 . At: www.ncbi.nlm.nih.gov/pmc/articles/
16. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel
for refractory partial-onset seizures: randomized phase III
study 304. Neurology 2012;79(6):589–96 . At: www.ncbi.nlm.
17. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of
adjunctive perampanel in patients with refractory partial-
onset seizures: results of randomized global phase III study
305. Epilepsia 2013;54(1):117–25 . At: http://onlinelibrary.
18. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized
phase III study 306: adjunctive perampanel for refractory
partial onset seizures. Neurology 2012;78:1408–15. At:
19. Satlin A, Kramer LD, Laurenza A. Development of
perampanel in epilepsy. Acta Neurol Scand 2013;127(Suppl.
197):3–8 . At: http://onlinelibrary.wiley.com/doi/10.1111/
20. Kerling F, Kasper BS. Efficacy of perampanel: a review of
clinical trial data. Acta Neurol Scand 2013:127 (Suppl.
197):25–29. At: http://onlinelibrary.wiley.com/doi/10.1111/
21. Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term
safety of perampanel and seizure outcomes in refractory
partial-onset seizures and secondarily generalized seizures:
results from phase III extension study 307. Epilepsia
2014;55(7):1058–68 . At: www.ncbi.nlm.nih.gov/pmc/
22. Sander L, Chandratre S, Craig J, et al. Consensus meeting
on the use of perampanel as adjunctive therapy in clinical
practice: recommendations from an expert panel. Adv
Clin Neurosci Rehabil 2015;15(1):19–23. At: www.acnr.
23. Rossi S, ed. Australian medicines handbook. Adelaide:
Australian Medicines Handbook; 2015.
24. Rugg-Gunn F. Adverse effects and safety profile
of perampanel: a review of pooled data. Epilepsia
2014;55(Suppl.1):13–15. At: http://onlinelibrary.wiley.com/
Links Archive Australian Pharmacist January 2016 Australian Pharmacist March 2016 Navigation Previous Page Next Page